Pfizer Inc. (NYSE:PFE) Shares Sold by Sierra Summit Advisors LLC

Sierra Summit Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 94.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,429 shares of the biopharmaceutical company’s stock after selling 359,609 shares during the period. Sierra Summit Advisors LLC’s holdings in Pfizer were worth $542,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Prospector Partners LLC raised its position in shares of Pfizer by 8.3% during the 4th quarter. Prospector Partners LLC now owns 88,555 shares of the biopharmaceutical company’s stock worth $2,349,000 after acquiring an additional 6,800 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co increased its stake in Pfizer by 48.8% in the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 982,000 shares of the biopharmaceutical company’s stock valued at $26,052,000 after purchasing an additional 322,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Pfizer by 2.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,798,470 shares of the biopharmaceutical company’s stock worth $100,752,000 after purchasing an additional 73,526 shares in the last quarter. Rahlfs Capital LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $1,060,000. Finally, Hurley Capital LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $86,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $22.99 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $22.28 and a 52-week high of $31.54. The company has a 50-day simple moving average of $25.87 and a 200-day simple moving average of $26.72. The company has a market capitalization of $130.39 billion, a PE ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.